Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Low-Dose eye drop stop constant watery eyes?

NCT ID NCT07676981

Symptom relief Sponsor: Rehan Ahmed Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 30, 2026 · Last updated Sep 11, 2026 · Updated 3 times

Summary

This trial tests whether low-dose atropine eye drops can reduce excessive tearing (epiphora) in adults. Participants use one of two strengths (0.005% or 0.01%) in their affected eye(s) for one week. The study compares how well each dose works and monitors for any side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
atropine sulfate ophthalmic solution
What this could lead to
If it works, this could offer a simple, low-dose eye drop treatment for people bothered by constant watery eyes.
What could go wrong
This is a small, early-phase trial with only 18 participants and a short one-week treatment period. Results may not apply to everyone, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

18 people

The number who actually took part.

Started

Jun 2026

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

You may be able to join if you: * Are 18 years or older * Have vision of 20/200 or better in at least one eye * Have watery eyes (epiphora) bad enough to need wiping or dabbing at least twice a day * Have watering caused by a functional/idiopathic, gustatory ("crocodile tears"), environmentally triggered (reflex), or obstructive cause - in one or both eyes * Have a healthy eye surface, with no significant dry eye, active eye infection, or active eye inflammation * Have adequate eyelid position and tone, where surgery is not the main treatment needed and reducing tear production is likely to help * Are willing and able to put drops in your eye(s) once each night for 7 days and attend the study visits * Can understand and follow the study procedures and communicate with study staff (an interpreter is allowed) You will not be able to join if you: * Have significant dry eye disease * Have had an active eye infection within the past 30 days * Have an active tear-sac infection, or a blocked tear duct that needs urgent surgery (a blocked tear duct that does not need surgery is allowed) * Currently use eye drops that affect tear production or eye-surface testing, unless you are willing to stop them for the study * Are allergic to, or should not take, atropine, similar (anticholinergic) medicines, or any ingredient in the study drops * Have narrow-angle or angle-closure glaucoma, where dilating the pupil would not be safe for you * Are pregnant or breastfeeding * Are taking part in another interventional study, or took part in one within 30 days before screening * Have any condition that, in the doctor's judgment, would make it unsafe for you to join or hard to follow the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epiphora are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

excessive tearing lacrimal apparatus disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epiphora

Contacts and locations

Locations

  • Greater Houston Eye Consultants

    Houston, Texas, 77098, United States

  • North Texas Eye Specialists

    Mesquite, Texas, 75150, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.